249 related articles for article (PubMed ID: 35998020)
21. Evaluation of circulating tumor DNA by electropherogram analysis and methylome profiling in high-risk neuroblastomas.
Trinidad EM; Juan-Ribelles A; Pisano G; Castel V; Cañete A; Gut M; Heath S; Font de Mora J
Front Oncol; 2023; 13():1037342. PubMed ID: 37251933
[TBL] [Abstract][Full Text] [Related]
22. Early detection and prognosis prediction for colorectal cancer by circulating tumour DNA methylation haplotypes: A multicentre cohort study.
Mo S; Dai W; Wang H; Lan X; Ma C; Su Z; Xiang W; Han L; Luo W; Zhang L; Wang R; Zhang Y; Zhang W; Yang L; Lu R; Guo L; Zheng Y; Huang M; Xu Y; Liang L; Cai S; Cai G
EClinicalMedicine; 2023 Jan; 55():101717. PubMed ID: 36386039
[TBL] [Abstract][Full Text] [Related]
23. Circulating tumour DNA testing in metastatic breast cancer: Integration with tissue testing.
Ranghiero A; Frascarelli C; Cursano G; Pescia C; Ivanova M; Vacirca D; Rappa A; Taormina SV; Barberis M; Fusco N; Rocco EG; Venetis K
Cytopathology; 2023 Nov; 34(6):519-529. PubMed ID: 37640801
[TBL] [Abstract][Full Text] [Related]
24. Circulating Tumor DNA Abundance and Potential Utility in De Novo Metastatic Prostate Cancer.
Vandekerkhove G; Struss WJ; Annala M; Kallio HML; Khalaf D; Warner EW; Herberts C; Ritch E; Beja K; Loktionova Y; Hurtado-Coll A; Fazli L; So A; Black PC; Nykter M; Tammela T; Chi KN; Gleave ME; Wyatt AW
Eur Urol; 2019 Apr; 75(4):667-675. PubMed ID: 30638634
[TBL] [Abstract][Full Text] [Related]
25. Targeted mutation detection in breast cancer using MammaSeq™.
Smith NG; Gyanchandani R; Shah OS; Gurda GT; Lucas PC; Hartmaier RJ; Brufsky AM; Puhalla S; Bahreini A; Kota K; Wald AI; Nikiforov YE; Nikiforova MN; Oesterreich S; Lee AV
Breast Cancer Res; 2019 Feb; 21(1):22. PubMed ID: 30736836
[TBL] [Abstract][Full Text] [Related]
26. ctDNA monitoring using patient-specific sequencing and integration of variant reads.
Wan JCM; Heider K; Gale D; Murphy S; Fisher E; Mouliere F; Ruiz-Valdepenas A; Santonja A; Morris J; Chandrananda D; Marshall A; Gill AB; Chan PY; Barker E; Young G; Cooper WN; Hudecova I; Marass F; Mair R; Brindle KM; Stewart GD; Abraham JE; Caldas C; Rassl DM; Rintoul RC; Alifrangis C; Middleton MR; Gallagher FA; Parkinson C; Durrani A; McDermott U; Smith CG; Massie C; Corrie PG; Rosenfeld N
Sci Transl Med; 2020 Jun; 12(548):. PubMed ID: 32554709
[TBL] [Abstract][Full Text] [Related]
27. Liquid biopsy in breast cancer: A comprehensive review.
Alimirzaie S; Bagherzadeh M; Akbari MR
Clin Genet; 2019 Jun; 95(6):643-660. PubMed ID: 30671931
[TBL] [Abstract][Full Text] [Related]
28. Discovery and validation of methylation signatures in blood-based circulating tumor cell-free DNA in early detection of colorectal carcinoma: a case-control study.
Sui J; Wu X; Wang C; Wang G; Li C; Zhao J; Zhang Y; Xiang J; Xu Y; Nian W; Cao F; Yu G; Lou Z; Hao L; Liu L; Li B; Zhang Z; Cai S; Liu H; Lan P; Zhang W
Clin Epigenetics; 2021 Feb; 13(1):26. PubMed ID: 33536049
[TBL] [Abstract][Full Text] [Related]
29. Somatic copy number alteration and fragmentation analysis in circulating tumor DNA for cancer screening and treatment monitoring in colorectal cancer patients.
Hallermayr A; Wohlfrom T; Steinke-Lange V; Benet-Pagès A; Scharf F; Heitzer E; Mansmann U; Haberl C; de Wit M; Vogelsang H; Rentsch M; Holinski-Feder E; Pickl JMA
J Hematol Oncol; 2022 Sep; 15(1):125. PubMed ID: 36056434
[TBL] [Abstract][Full Text] [Related]
30. The potential of ctDNA analysis in breast cancer.
Tzanikou E; Lianidou E
Crit Rev Clin Lab Sci; 2020 Jan; 57(1):54-72. PubMed ID: 31674269
[TBL] [Abstract][Full Text] [Related]
31. Monitoring treatment efficacy and resistance in breast cancer patients via circulating tumor DNA genomic profiling.
Chen Z; Sun T; Yang Z; Zheng Y; Yu R; Wu X; Yan J; Shao YW; Shao X; Cao W; Wang X
Mol Genet Genomic Med; 2020 Feb; 8(2):e1079. PubMed ID: 31867841
[TBL] [Abstract][Full Text] [Related]
32. Circulating tumor DNA in early-stage breast cancer: new directions and potential clinical applications.
Croessmann S; Park BH
Clin Adv Hematol Oncol; 2021 Mar; 19(3):155-161. PubMed ID: 33739964
[TBL] [Abstract][Full Text] [Related]
33. [Current situation and prospect of breast cancer liquid biopsy].
Zhou B; Xin L; Xu L; Ye JM; Liu YH
Zhonghua Wai Ke Za Zhi; 2018 Feb; 56(2):106-109. PubMed ID: 29397622
[TBL] [Abstract][Full Text] [Related]
34. Identification of mutations in circulating cell-free tumour DNA as a biomarker in hepatocellular carcinoma.
Howell J; Atkinson SR; Pinato DJ; Knapp S; Ward C; Minisini R; Burlone ME; Leutner M; Pirisi M; Büttner R; Khan SA; Thursz M; Odenthal M; Sharma R
Eur J Cancer; 2019 Jul; 116():56-66. PubMed ID: 31173963
[TBL] [Abstract][Full Text] [Related]
35. Association of Circulating Tumor DNA With Disease-Free Survival in Breast Cancer: A Systematic Review and Meta-analysis.
Cullinane C; Fleming C; O'Leary DP; Hassan F; Kelly L; O'Sullivan MJ; Corrigan MA; Redmond HP
JAMA Netw Open; 2020 Nov; 3(11):e2026921. PubMed ID: 33211112
[TBL] [Abstract][Full Text] [Related]
36. Enhanced Performance of DNA Methylation Markers by Simultaneous Measurement of Sense and Antisense DNA Strands after Cytosine Conversion.
Jensen SØ; Øgaard N; Nielsen HJ; Bramsen JB; Andersen CL
Clin Chem; 2020 Jul; 66(7):925-933. PubMed ID: 32460325
[TBL] [Abstract][Full Text] [Related]
37. Osteosarcoma: Novel prognostic biomarkers using circulating and cell-free tumour DNA.
Lyskjær I; Kara N; De Noon S; Davies C; Rocha AM; Strobl AC; Usher I; Gerrand C; Strauss SJ; Schrimpf D; von Deimling A; Beck S; Flanagan AM
Eur J Cancer; 2022 Jun; 168():1-11. PubMed ID: 35421838
[TBL] [Abstract][Full Text] [Related]
38. High concordance of actionable genomic alterations identified between circulating tumor DNA-based and tissue-based next-generation sequencing testing in advanced non-small cell lung cancer: The Korean Lung Liquid Versus Invasive Biopsy Program.
Park S; Olsen S; Ku BM; Lee MS; Jung HA; Sun JM; Lee SH; Ahn JS; Park K; Choi YL; Ahn MJ
Cancer; 2021 Aug; 127(16):3019-3028. PubMed ID: 33826761
[TBL] [Abstract][Full Text] [Related]
39. Resectable lung lesions malignancy assessment and cancer detection by ultra-deep sequencing of targeted gene mutations in plasma cell-free DNA.
Peng M; Xie Y; Li X; Qian Y; Tu X; Yao X; Cheng F; Xu F; Kong D; He B; Liu C; Cao F; Yang H; Yu F; Xu C; Tian G
J Med Genet; 2019 Oct; 56(10):647-653. PubMed ID: 30981987
[TBL] [Abstract][Full Text] [Related]
40. Circulating tumor DNA detection is correlated to histologic types in patients with early-stage non-small-cell lung cancer.
Zhang B; Niu X; Zhang Q; Wang C; Liu B; Yue D; Li C; Giaccone G; Li S; Gao L; Zhang H; Wang J; Yang H; Wu R; Ni P; Wang C; Ye M; Liu W
Lung Cancer; 2019 Aug; 134():108-116. PubMed ID: 31319968
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
